Maa: Australia
Kieli: englanti
Lähde: Department of Health (Therapeutic Goods Administration)
gliclazide, Quantity: 80 mg
Arrotex Pharmaceuticals Pty Ltd
Tablet, uncoated
Excipient Ingredients: sodium starch glycollate type A; purified talc; magnesium stearate; povidone; lactose monohydrate; microcrystalline cellulose; purified water
Oral
100 tablets
(S4) Prescription Only Medicine
INDICATIONS: Diabetes mellitus of the maturity onset type, which cannot be controlled by diet alone.
Visual Identification: A white to off white round, bevel-edged, uncoated tablet with cross score (+) on one face and plain on the other; Container Type: Blister Pack; Container Material: PVC/Al; Container Life Time: 3 Years; Container Temperature: Store below 30 degrees Celsius
Registered
2020-06-23
Page 1 of 6 APX-GLICLAZIDE gliclazide CONSUMER MEDICINE INFORMATION (CMI) WHAT IS IN THIS LEAFLET This leaflet answers some common questions about APX-GLICLAZIDE. It does not contain all of the available information. It does not take the place of talking to your doctor, pharmacist or diabetes educator. All medicines have benefits and risks. Your doctor has weighed the risks of you taking APX- GLICLAZIDE against the benefits they expect it will have for you . TALK TO YOUR DOCTOR, PHARMACIST OR DIABETES EDUCATOR IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE. KEEP THIS LEAFLET WITH YOUR MEDICINE. You may need to read it again. WHAT APX-GLICLAZIDE IS USED FOR APX-GLICLAZIDE is used to control blood glucose in people with Type 2 diabetes mellitus. This type of diabetes is also called non-insulin dependent diabetes mellitus (NIDDM) or maturity onset diabetes. APX-GLICLAZIDE is used when diet and exercise are not enough to control your blood glucose levels. It can be used alone, or in combination with other medicines for treating diabetes. APX-GLICLAZIDE is available only with a doctor's prescription. HOW APX-GLICLAZIDE WORKS APX-GLICLAZIDE belongs to a group of medicines called sulphonylureas. These medicines lower blood glucose by increasing the amount of insulin produced by your pancreas. If your blood glucose is not properly controlled, you may experience hypoglycaemia (low blood glucose) or hyperglycaemia (high blood glucose). HYPOGLYCAEMIA Hypoglycaemia (low blood glucose) can occur suddenly. Signs may include: • weakness, trembling or shaking • sweating • lightheadedness, dizziness, headache or lack of concentration • irritability, tearfulness or crying • hunger • numbness around the lips and tongue. If not treated promptly, these may progress to: • loss of co-ordination • slurred speech • confusion • fits or loss of consciousness HYPERGLYCAEMIA Hyperglycaemia (high blood glucose) usually occurs more slowly than hypoglycaemia. Signs of hyperglycaemia may include: • lethargy or tirednes Lue koko asiakirja
APX-GLICLAZIDE product Information 1 AUSTRALIAN PRODUCT INFORMATION APX-GLICLAZIDE (GLICLAZIDE) TABLET S 1 NAME OF THE MEDICINE Gliclazide 2 QUALITATIVE AND QUANTITATIVE COMPOSITION APX-GLICLAZIDE tablets contain 80 mg of gliclazide. EXCIPIENTS WITH KNOWN EFFECT: lactose monohydrate. For the full list of excipients, see Section 6.1 L IST OF EXCIPIENTS . 3 PHARMACEUTICAL FORM Uncoated tablets A white to off white round, bevel-edged, uncoated tablet with cross score (+) on one face and plain on the other 4 CLINICAL PARTICULARS 4.1 T HERAPEUTIC INDICATIONS Diabetes mellitus of the maturity onset type, which cannot be controlled by diet alone. 4.2 D OSE AND METHOD OF ADMINISTRATION For adult use only. The dosage of gliclazide should be carefully titrated to maintain optimal control at the various possible dose levels. Dosage should be initiated at 40 mg (1/2 tablet) daily and may be increased if necessary up to 320 mg (four tablets) daily. Doses up to 160 mg daily may be taken in a single dose but preferably at the same time each morning. Doses in excess of 160 mg should be taken in divided doses in the morning and evening. In general, the dosage will depend on the severity of the glycaemia with ongoing adjustments made in order to obtain the optimal response at the lowest dosage. Treatment with gliclazide does not obviate the necessity of maintaining standard dietary regulations. 4.3 C ONTRAINDICATIONS Gliclazide should not be used in diabetes complicated by acidosis, ketosis or coma, or in patients with a history of repeated episodes of ketoacidosis or coma. APX-GLICLAZIDE product Information 2 Juvenile onset diabetes and unstable or brittle diabetes. As sulfonylurea hypoglycaemic agents are not effective in juvenile onset, unstable or brittle diabetes, gliclazide should not be used in these conditions. Hypersensitivity: Gliclazide should not be used with patients with known sensitivity to sulfonylureas. Impaired renal function: Gliclazide is contraindicated in severe renal insufficiency. Caution should be exercise Lue koko asiakirja